SEC EDGARJUN 111 min read$WGS

Stueland Katherine sold $196K of WGS

Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 3,639 shares of GeneDx Holdings Corp. (WGS) at $53.77 ($0.20M total) on 2026-06-09.

Original reporting

SEC EDGAR · Stueland Katherine

Published Jun 11, 2026, 8:11 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 11, 2026, 8:26 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$WGS

Bearish

medium confidence

Mentioned

$WGS

Relevance

4/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$WGSBearishLow

Why it matters

Traders may monitor for follow-on insider activity, but the filing alone does not change the company’s fundamentals.

Market read

Primary insider-sale disclosure (CEO selling) with transaction details; likely small sentiment impact only.

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article still lacks context (taxes, diversification, planned expenses) that often explains sales.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-11 after-hours; transaction dated 2026-06-09

Background

The article is an SEC Form 4 insider transaction disclosure for GeneDx Holdings Corp. (WGS).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$WGSBearishMedium confidence

Context

GeneDx CEO Katherine Stueland filed an open-market sale of 3,639 shares at $53.77 on 2026-06-09 (Form 4, no 10b5-1 plan).

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and quickly absorbed unless follow-on insider selling accelerates.

Evidence & confidence

The disclosure is primary (SEC Form 4) and includes size/price, but the article provides no accompanying operational/regulatory/financial change and the sale is not tied to a stated corporate event.

Market effects

Sector

Minimal; single-insider sale does not reset sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity/portfolio rebalancing and are not necessarily bearish without a pattern or linkage to adverse news.

Key entities

issuer
GeneDx Holdings Corp.
Company whose CEO filed an insider sale (Form 4).
insider
Katherine Stueland
Chief Executive Officer and reporting person; sold shares in an open-market transaction.

Read at source ← All news

AUG 3

$PLTRMed

After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

investing.com6 min

AUG 3

$WGSHighAI 9/10

GeneDx Holdings Corp. (WGS): Results of Operations and Financial Condition

GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026pressrele.htm EX-99.1 Document Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of

SEC EDGAR 8-K6 min

JUL 28

$WGSMed

GeneDx’s $4.8M AI-Hype Settlement Exposes Governance Failures -By Fransiscus Nanga Roka

GeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.

opinionnigeria.com5 min

JUL 18

$WGSMed

GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against GeneDx Holdings Corp. (NASDAQ: WGS) in the District of Connecticut. The class period runs April 16, 2025 to May 4, 2026, with an Aug. 3, 2026 lead-plaintiff deadline. Allegations center on statements about the viability of GeneDx’s up-to-$51 million acquisition of Fabric Genomics and a May 4, 2026 impairment write-off of $31.3 million.

prnewswire.com4 min

JUN 8

$WGSLowAI 8/10

Casdin Capital, LLC purchased $11.1M of WGS (indirect holdings)

Casdin Capital, LLC purchased 200,000 indirectly-held shares of GeneDx Holdings Corp. (WGS) at an average of $55.55 ($52.86–$56.44, $11.11M total) across 2 trades over 2026-06-04 to 2026-06-05.

SEC EDGAR2 min

JUN 4

$WGSMedAI 9/10

GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS

GeneDx Holdings (NASDAQ: WGS) shares fell 49% on May 5, 2025 after the company reported a Q1 2026 earnings miss, a tenfold increase in net loss, and cut full-year 2026 guidance by 12%, according to the report. Hagens Berman opened a securities-law investigation, citing a shift in product mix and reduced growth expectations. The article notes ARR was $3,750 in 2025 and was expected to be flat for 2026.